Remove Immune Response Remove Radiology Remove Research
article thumbnail

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

The Pharma Data

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study.

article thumbnail

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. Only 6 related Grade 1 adverse events in 5 subjects were observed, primarily mild injection site reactions (e.g., ClinicalTrials.gov identifier: NCT04336410.

DNA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Low-dose radiotherapy combined with immunotherapy eradicates metastatic cancer in mice

Bioengineer

But some patients develop resistance to current immunotherapies and others have cancers characterized by immunologically “cold” tumors, which evade or suppress the patient’s immune response against his or her cancer. Additional authors on this research are Peter Carlson, Joseph Grudinski, Ph.D., ” ###.

article thumbnail

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The Pharma Data

W911QY-21-9-0001. AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

article thumbnail

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

The Pharma Data

The half-life extension more than triples the durability of its action compared to conventional antibodies;(11-13) data from the PROVENT Phase III trial show protection lasting at least six months.(14) W911QY-21-9-0001.

article thumbnail

How Advanced Diagnostics are Shaping the Future of Precision Medicine and Gene Therapy

Cloudbyz

This revolution is enabling the growth of innovative biomarker-based precision medicine and cell and gene therapy, transforming both clinical research and post-market care. Automated Image Analysis: In fields like radiology and pathology, AI-powered image analysis tools can detect subtle changes and anomalies with high accuracy.

article thumbnail

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in.

The Pharma Data

More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. The primary analysis was based on 5,172 participants who did not have SARS-CoV-2 infection at baseline. W911QY-21-9-0001.

Trials 52